Distance from leukapheresis to manufacturing site is somewhat of a qualitative limiting factor. They will likely ramp to two or more manufacturing sites for the U.S. once (assuming) approved here. Prior to that, I’d assume patients will travel to undergo leukaoheresis closer to the manufacturing site. IMO.
Market Data 
Markets 
AI
